Topics

Clinical Trials About "Health Mindstrong Major Depressive Disorder" RSS

05:35 EST 28th February 2020 | BioPortfolio

We list hundreds of Clinical Trials about "Health Mindstrong Major Depressive Disorder" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "Health Mindstrong Major Depressive Disorder" on BioPortfolio

We have published hundreds of Health Mindstrong Major Depressive Disorder news stories on BioPortfolio along with dozens of Health Mindstrong Major Depressive Disorder Clinical Trials and PubMed Articles about Health Mindstrong Major Depressive Disorder for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Health Mindstrong Major Depressive Disorder Companies in our database. You can also find out about relevant Health Mindstrong Major Depressive Disorder Drugs and Medications on this site too.

Showing "Health Mindstrong Major Depressive Disorder" Clinical Trials 1–25 of 27,000+

Extremely Relevant

Testing the Value of Smartphone Assessments of People With Mood Disorders

The purpose of this study is two-fold: 1. To identify the best smartphone data features (based on keyboard, sensor, voice/speech data) that correlate with mood, anxiety, and cognitive assessments in patients with Major Depressive Disorder (MDD) and Bipolar Depression (BD). 2. To identify the best smartphone data features (based on keyboard, sensor, voice/speech at a) that predict relapse and remission in MDD or BD.


Impact of Atypical Antipsychotic Therapy on Health Outcomes and Costs Among Patients With Major Depressive Disorder

The primary objective is to examine changes in pre/post-augmentation healthcare costs and resource utilization in patients diagnosed with major depressive disorder (MDD) who augment their current antidepressant therapy with an atypical antipsychotic.

Study Of 323U66 SR In Major Depressive Disorder

This study was designed to evaluate the efficacy and safety in major depressive disorder patients.


Escitalopram in the Treatment of Adolescents With Major Depressive Disorder or Anxiety Disorders

Escitalopram has been approved by FDA in the treatment of adolescents with major depressive disorder since March 2009. To date, there are only 3 clinical trials assessing the effect and validity of escitalopram on major depressive disorder, which of them has resulted in inconsistent findings. In the present study, the authors aimed to assess the effect and validity of this drug in the treatment of adolescents with major depressive disorder and or anxiety disorders.

Cognitive and Mood Assessment Data in Major Depressive Disorder Using Digital Wearable Technology

The purpose of this study is to evaluate feasibility and compliance with a novel method for assessing mood and cognition in participants with major depressive disorder (MDD).

Randomized, Placebo-Controlled Trial of an AMPAkine in Major Depressive Disorder

The purpose of this study is to test a candidate drug, Org 24448,in a phase II clinical trial in adult patients with moderately treatment-resistant unipolar major depressive disorder.

An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder

A Placebo Controlled Study Evaluating Efficacy, Safety and Tolerability of Medication in Patients with Major Depressive Disorder (MDD)

An 8 Week Study Of Adults Diagnosed With Major Depressive Disorder

A Placebo Controlled Study Evaluating Efficacy, Safety and Tolerability of Medication in Patients with Major Depressive Disorder (MDD)

A Study in Patients With Major Depressive Disorder

This is a Phase 2a, placebo-controlled, single-blind study in up to 24 patients with major depressive disorder (MDD).

Study of BMS-562086 in the Treatment of Outpatients With Major Depressive Disorder

The purpose of this clinical research study is to learn whether BMS-562086 is both safe and effective in treating outpatients with major depressive disorder.

Study Of The Effects Of A New Antidepressant Therapy In Patients With Major Depressive Disorder (MDD)

The purpose of this study is to assess the efficacy, safety and tolerability of GW679769 patients with Major depressive Disorder (MDD).

Study Evaluating DVS-233 SR in Elderly Outpatients With Major Depressive Disorder

To evaluate the overall safety and tolerability profile of two dose levels of DVS-233 SR during 6 months of open-label treatment in elderly outpatients with major depressive disorder.

Escitalopram Combination Comparison Study for Adult Patients With Major Depressive Disorder

The purpose of this study is to evaluate the effectiveness, safety and tolerability of an escitalopram combination treatment compared to single treatments, and to placebo in patients with major depressive disorder.

Citalopram Titration in Early Non-responder Patients With Major Depressive Disorders

Major depressive disorder is a common mental disorder and the leading cause of disability worldwide. According to the Canadian Network for Mood and Anxiety Treatment, early improvement following an antidepressant treatment is correlated with response and remission. Escalation of an antidepressant dose after 2 weeks, as opposed to 4 to 8 weeks, is proposed to favor early improvement. However, this has never been tested systematically in a controlled study involving major depress...

The Effect of Fish Oil in Major Depressive Disorder

The whole three-year study was divided into two major parts: (A) the 12-week, double-blind, randomized controlled, parallel omega-3 fatty acid monotherapy study in 60 patients with mild to moderate major depressive disorder. (B) The double-blind, randomized controlled, parallel omega-3 fatty acid add-on prevention study in 60 patients with major depressive disorder in recovery status. The goals of this study were to examine the therapeutic and recurrence prevention effects of ...

Ketamine for Major Depressive Disorder

The purpose of this study is to measure the amount of ketamine in blood over time in subjects diagnosed with Major Depressive Disorder (MDD) and explore the anti-depressive effects of ketamine delivered by transdermal patch.

Trial of Surf and Hike Therapy for Major Depressive Disorder

This study uses a randomized controlled trial design to compare the psychological effects of surf therapy to hike therapy in active duty service members who have been diagnosed with major depressive disorder.

Effect of Ketamine vs. Active Placebo on Suicidal Ideation in Depressed Inpatients With Major Depressive Disorder or Bipolar Depression.

Depression and suicidal ideation/attempt/death are major causes of morbidity and mortality from psychiatric illnesses. In 2009, the World Health Organization listed depression as the leading cause of years lost due to disability worldwide. Suicide is the 9th most common cause of death in Canada with 1.6% of Canadians ultimately dying from suicide (Statistics Canada, 2012) and the 2nd most common cause of death in young people after accidental deaths. This information highlights...

An 8 Week Depression Study In Adults Diagnosed With Major Depressive Disorder

A Placebo Controlled Study Evaluating Efficacy, Safety and Tolerability of Radafaxine in Patients with Major Depressive Disorder (MDD)

Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)

Evaluating the efficacy of vortioxetine 10 mg/day and 20 mg/day versus placebo on depressive symptoms in adolescents (age ≥12 and ≤17 years) with a DSM-5™ (Diagnostic and Statistical Manual of Mental Disorders, 5th edition) diagnosis of Major depressive disorder (MDD).

Effects of Psilocybin in Major Depressive Disorder

The proposed pilot study will assess whether people with major depressive disorder experience psychological and behavioral benefits and/or harms from psilocybin. This study will investigate acute and persisting effects of psilocybin on depressive symptoms and other moods, attitudes, and behaviors. Our primary hypothesis is that psilocybin will lead to rapid and sustained antidepressant response, as measured with standard depression rating scales.

A Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder

The primary purpose is to study the efficacy, safety, and tolerability of LY2216684 as an adjunctive treatment for patients with major depressive disorder (MDD), who were identified as partial responders to an adequate course of treatment with a selective serotonin reuptake inhibitor (SSRI) (as defined by history).

A Study Of A New Medicine (GW597599B) For The Treatment Of Major Depressive Disorder

A Placebo Controlled Study Evaluating Efficacy And Safety of Medication In Patients With Major Depressive Disorder (MDD)

A Study of Brexpiprazole in Patients With Major Depressive Disorder

The purpose of this 14 week, randomized, double-blind, placebo controlled study is to assess the safety and efficacy of brexipiprazole to placebo as adjunctive treatment to an assigned open-label marketed antidepressant therapy (ADT) in patients with Major Depressive Disorder.

A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Major Depressive Disorder

The study will evaluate the efficacy, safety, and tolerability of 450 milligrams (mg) of Rapastinel, compared to placebo in adult patients with major depressive disorder (MDD) who are at imminent risk of suicide.


More From BioPortfolio on "Health Mindstrong Major Depressive Disorder"

Quick Search